RU2002113759A - Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII - Google Patents
Соединения имидазола в качестве ингибиторов фосфодиэстеразы VIIInfo
- Publication number
- RU2002113759A RU2002113759A RU2002113759/04A RU2002113759A RU2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759/04 A RU2002113759/04 A RU 2002113759/04A RU 2002113759 A RU2002113759 A RU 2002113759A RU 2002113759 A RU2002113759 A RU 2002113759A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compounds
- diseases
- imidazole
- solvates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
Claims (7)
1. Соединения имидазола формулы
в которых R1 и R2, независимо друг от друга, обозначают А1, ОА1, SA1
или Hal;
А1 обозначает Н, А, алкенил, циклоалкил или алкиленциклоалкил;
А обозначает алкил, содержащий 1-10 атомов углерода;
Hal обозначает F, CI, Вг или I;
Х обозначает О, S, SO или SO2,
и их физиологически приемлемые соли и/или сольваты.
2. Соединения имидазола формулы I по п.1 и их физиологически приемлемые соли и сольваты в качестве медицинских препаратов.
3. Медицинские препараты по п.2 для ингибирования фосфодиэстеразы VII.
4. Медицинские препараты по п.3 для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
5. Фармацевтические препараты, содержащие, по крайней мере, один медицинский препарат по одному из пп.3 и 4, которые могут содержать также эксципиенты и/или вспомогательные вещества и другие активные ингредиенты.
6. Применение соединений формулы I по п.1 и/или их физиологически приемлемых солей или сольватов в приготовлении медицинских препаратов для лечения аллергических заболеваний, астмы, хронического бронхита, атопического дерматита, псориаза и других кожных заболеваний, воспалительных заболеваний, аутоиммунных болезней, таких, как, например, ревматоидный артрит, рассеянный склероз, болезнь Крона, сахарный диабет или язвенный колит, остеопороз, реакции отторжения трансплантированной ткани, кахексия, рост опухолей или опухолевых метастазов, сепсис, расстройства памяти, атеросклероз и СПИД.
7. Способ получения соединений формулы I по п.1 и их солей, отличающийся тем, что проводят реакцию соединений формулы II
в которой R1, R2 и Х соответствуют приведенным выше определениям;
L обозначает Cl, Br, ОН, SCH3 или активную этерифицированную группу ОН, с имидазолом,
и/или соединение формулы I преобразуют в одну из его солей.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19954707A DE19954707A1 (de) | 1999-11-13 | 1999-11-13 | Imidazolverbindungen als Phosphodiesterase VII-Hemmer |
DE19954707.6 | 1999-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2002113759A true RU2002113759A (ru) | 2004-01-10 |
Family
ID=7928973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2002113759/04A RU2002113759A (ru) | 1999-11-13 | 2000-10-31 | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII |
Country Status (23)
Country | Link |
---|---|
US (1) | US6884800B1 (ru) |
EP (1) | EP1228073B1 (ru) |
JP (1) | JP4819272B2 (ru) |
KR (1) | KR20020049051A (ru) |
CN (1) | CN1390222A (ru) |
AR (1) | AR026421A1 (ru) |
AT (1) | ATE245653T1 (ru) |
AU (1) | AU775886B2 (ru) |
BR (1) | BR0015487A (ru) |
CA (1) | CA2391087A1 (ru) |
CZ (1) | CZ20021474A3 (ru) |
DE (2) | DE19954707A1 (ru) |
DK (1) | DK1228073T3 (ru) |
ES (1) | ES2200968T3 (ru) |
HU (1) | HUP0203422A3 (ru) |
MX (1) | MXPA02004728A (ru) |
NO (1) | NO20022232L (ru) |
PL (1) | PL355098A1 (ru) |
PT (1) | PT1228073E (ru) |
RU (1) | RU2002113759A (ru) |
SK (1) | SK6012002A3 (ru) |
WO (1) | WO2001036425A2 (ru) |
ZA (1) | ZA200204729B (ru) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2217956B1 (es) * | 2003-01-23 | 2006-04-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo. |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
CA2681650C (en) * | 2007-03-27 | 2016-11-22 | Omeros Corporation | The use of pde7 inhibitors for the treatment of movement disorders |
DE102007047738A1 (de) * | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US9220715B2 (en) | 2010-11-08 | 2015-12-29 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
CN103547267A (zh) | 2010-11-08 | 2014-01-29 | 奥默罗斯公司 | 使用pde7抑制剂治疗成瘾和冲动控制障碍 |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
KR102640696B1 (ko) | 2017-07-12 | 2024-02-27 | 다트 뉴로사이언스, 엘엘씨 | Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물 |
WO2024038089A1 (en) | 2022-08-18 | 2024-02-22 | Mitodicure Gmbh | Use of a therapeutic agent with phosphodiesterase-7 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2919271A (en) | 1957-12-05 | 1959-12-29 | Smith Kline French Lab | 3-amino-1, 2-dihydro-3h-pyrido [3, 2, 1-kl]-phenothiazines |
ES2067744T3 (es) * | 1989-06-09 | 1995-04-01 | Upjohn Co | Aminas heterociclicas con actividad sobre el sistema nervioso central. |
US5318965A (en) * | 1990-08-24 | 1994-06-07 | Abbott Laboratories | Quinobenzoxazine, antineoplastic agents |
ZA9810766B (en) * | 1997-11-28 | 1999-05-25 | Mochida Pharm Co Ltd | Novel compounds having cgmp-pde inhibitory activity |
-
1999
- 1999-11-13 DE DE19954707A patent/DE19954707A1/de not_active Withdrawn
-
2000
- 2000-10-31 WO PCT/EP2000/010765 patent/WO2001036425A2/de not_active Application Discontinuation
- 2000-10-31 BR BR0015487-3A patent/BR0015487A/pt not_active Application Discontinuation
- 2000-10-31 DE DE50003036T patent/DE50003036D1/de not_active Expired - Lifetime
- 2000-10-31 SK SK601-2002A patent/SK6012002A3/sk unknown
- 2000-10-31 CN CN00815534A patent/CN1390222A/zh active Pending
- 2000-10-31 JP JP2001538914A patent/JP4819272B2/ja not_active Expired - Fee Related
- 2000-10-31 HU HU0203422A patent/HUP0203422A3/hu unknown
- 2000-10-31 PL PL00355098A patent/PL355098A1/xx unknown
- 2000-10-31 RU RU2002113759/04A patent/RU2002113759A/ru unknown
- 2000-10-31 CZ CZ20021474A patent/CZ20021474A3/cs unknown
- 2000-10-31 AT AT00975978T patent/ATE245653T1/de not_active IP Right Cessation
- 2000-10-31 EP EP00975978A patent/EP1228073B1/de not_active Expired - Lifetime
- 2000-10-31 US US10/129,629 patent/US6884800B1/en not_active Expired - Fee Related
- 2000-10-31 DK DK00975978T patent/DK1228073T3/da active
- 2000-10-31 ES ES00975978T patent/ES2200968T3/es not_active Expired - Lifetime
- 2000-10-31 PT PT00975978T patent/PT1228073E/pt unknown
- 2000-10-31 KR KR1020027006131A patent/KR20020049051A/ko not_active Application Discontinuation
- 2000-10-31 MX MXPA02004728A patent/MXPA02004728A/es not_active Application Discontinuation
- 2000-10-31 CA CA002391087A patent/CA2391087A1/en not_active Abandoned
- 2000-10-31 AU AU13907/01A patent/AU775886B2/en not_active Ceased
- 2000-11-10 AR ARP000105929A patent/AR026421A1/es unknown
-
2002
- 2002-05-10 NO NO20022232A patent/NO20022232L/no not_active Application Discontinuation
- 2002-06-12 ZA ZA200204729A patent/ZA200204729B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US6884800B1 (en) | 2005-04-26 |
HUP0203422A2 (hu) | 2003-02-28 |
PT1228073E (pt) | 2003-12-31 |
WO2001036425A2 (de) | 2001-05-25 |
JP4819272B2 (ja) | 2011-11-24 |
EP1228073B1 (de) | 2003-07-23 |
AU775886B2 (en) | 2004-08-19 |
CA2391087A1 (en) | 2001-05-25 |
DE50003036D1 (de) | 2003-08-28 |
DK1228073T3 (da) | 2003-11-03 |
CN1390222A (zh) | 2003-01-08 |
NO20022232D0 (no) | 2002-05-10 |
PL355098A1 (en) | 2004-04-05 |
EP1228073A2 (de) | 2002-08-07 |
JP2003514821A (ja) | 2003-04-22 |
ATE245653T1 (de) | 2003-08-15 |
SK6012002A3 (en) | 2002-09-10 |
BR0015487A (pt) | 2002-07-02 |
ES2200968T3 (es) | 2004-03-16 |
MXPA02004728A (es) | 2002-08-30 |
CZ20021474A3 (cs) | 2002-07-17 |
HUP0203422A3 (en) | 2004-12-28 |
KR20020049051A (ko) | 2002-06-24 |
WO2001036425A3 (de) | 2002-01-10 |
AR026421A1 (es) | 2003-02-12 |
ZA200204729B (en) | 2003-11-26 |
DE19954707A1 (de) | 2001-05-17 |
NO20022232L (no) | 2002-05-10 |
AU1390701A (en) | 2001-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2002113759A (ru) | Соединения имидазола в качестве ингибиторов фосфодиэстеразы VII | |
RU2002113750A (ru) | Производные пиррола в качестве ингибиторов фосфодиэстеразы VII | |
ES2461967T3 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
EP1439837B1 (en) | Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors | |
AU2018306619A1 (en) | Immunomodulator compounds | |
AR016133A1 (es) | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria | |
GB9900334D0 (en) | Tricylic vascular damaging agents | |
CA2160928A1 (en) | Compounds as pde iv and tnf inhibitors | |
WO1998052549B1 (de) | Verwendung von fumarsäurederivaten | |
CN104837825A (zh) | 鲁顿酪氨酸激酶抑制剂 | |
RU2000132188A (ru) | Производные эпотилонов, их синтез и применение | |
AR014903A1 (es) | Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria | |
SK281318B6 (sk) | Amidy kyseliny hydroxyalkylidénkyanoctovej, farmaceutický prostriedok obsahujúci tieto zlúčeniny a ich použitie | |
EP1438295A2 (en) | Azole derivatives and pharmaceutical compositions containing them | |
KR890013035A (ko) | 인돌로카르바졸 유도체와 그 제조방법 및 그들을 함유하는 약제조성물 | |
RU99105211A (ru) | Арилалканоилпиридазины | |
RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
JPH01246281A (ja) | 向精神性作用化合物及びその調製法 | |
CN101341150A (zh) | 硝基咪唑化合物 | |
RU2002113746A (ru) | Производные изоксазола в качестве ингибиторов фосфодиэстеразы VII | |
JP3122161B2 (ja) | γ−ラクトン免疫抑制剤 | |
RU2222541C2 (ru) | Оптически активные производные пирролопиридазина, способы их получения, фармацевтическая композиция и агент на их основе, способ лечения или профилактики язвенной болезни | |
RU2002105518A (ru) | Гетероциклические соединения, ингибирующие ангиогенез | |
RU2222537C2 (ru) | Новые производные морфолина, способ их получения и содержащие их фармацевтические композиции | |
CN1070909A (zh) | 硫脲衍生物和含该硫脲衍生物的抗微生物剂和抗溃疡剂 |